December 11, 2006 – Nuvelo and Bayer reported alfimeprase failed a Phase III test for acute peripheral arterial occlusion; Neopharm took a 68% hit after announcing that its brain cancer drug did not outperform the current standard of care; and Merck and Idera Pharma will collaborate to discover and develop Toll-like Receptor agonists for vaccines. The annual ASH meeting was held over the weekend, creating a flood of news. Companies reporting clinical news included: Bristol-Myers Squibb, Geron, EntreMed, Novartis, Millennium, Kosan, Genzyme, Immunomedics, Merck, Vertex, Pharmion, BioCryst, Alexion, GPC Biotech, Cell Therapeutics, and Biogen Idec. The Centient Biotech 200™ gained 2 points to end the session at 3989, a rise of .05%. More details...
